β-Lactam Antibiotics

References

• Tomasz A. From penicillin-binding proteins to the lysis and death of bacteria: A 1979 view. Rev Infect Dis 1979; 1: 434–467
   PubMedGoogle Scholar
• Chambers H F, Neu H C. Penicillins. Principles and Practice of Infectious Diseases4th ed., G L Mandell, J E Bennett, R Dolin. Churchill Livingstone, New York 1995; 233–246
   Google Scholar
• Donowitz G R, Mandell G L. Beta-lacatam antibiotics. N Engl J Med 1986; 318: 419–426
   Google Scholar
• Mandell G L, Sande M A. Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. The Pharmacological Basis of Therapeutics7th ed., A G Gilman, L S Goodman, W Rail, F Murad. Macmillan, New York 1985; 1115–1149
   Google Scholar
• Jacoby G A, Archer G L. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991; 324: 601–612
   PubMed Web of Science ®Google Scholar
• Neu H C. The crisis in antibiotic resistance. Science 1992; 257: 1064–1073
   PubMed Web of Science ®Google Scholar
• Gold H S, Moellering R C, Jr. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445–1453
   PubMed Web of Science ®Google Scholar
• Medeiros A A. Evolution and dissemination of β-lactamases accelerated by generations of P-lactam antibiotics. Clin Infect Dis 1997; 24: S19–S45
   PubMed Web of Science ®Google Scholar
• Hartman B J, Tomasz A. Low-affinity penicillin-binding protein associated with β -lactam resistance in Staphylococcus aureus. J Bacteriol 1984; 158: 513–516
   PubMed Web of Science ®Google Scholar
• Handwerger S, Tomasz A. Alterations in penicillin-binding proteins of clinical and laboratory isolates of pathogenic Streptococcus pneumoniae with low levels of penicillin resistance. J Infect Dis 1986; 153: 83–89
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby G A, Medeiros A A. A functional classification scheme for β -lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–1233
   PubMed Web of Science ®Google Scholar
• Meyer K S, Urban C, Eagan J A, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353–358
   PubMed Web of Science ®Google Scholar
• Chambers H F, Neu H C. Other B-lactam antibiotics. Principles and Practice of Infectious Diseases4th ed., G L Mandell, J E Bennett, R Dolin. Churchill Livingstone, New York 1995; 264–272
   Google Scholar
• Brewer N S, Hellinger W C. The monobactams. Mayo Clin Proc. 1991; 66: 1152–1157
   PubMed Web of Science ®Google Scholar
• Pryka R D, Haig G M, Meropenem. A new carbapenem antimicrobial. Ann Pharmacother 1994; 28: 1045–1054
   PubMed Web of Science ®Google Scholar
• Anonymous Meropenem–A new parenteral broad-spectrum antibiotic. Medical Letter. 1996; 38: 88–90
   Google Scholar
• Norrby S R. Carbapenems. Med Clin North Am 1995; 79: 745–759
   PubMed Web of Science ®Google Scholar
• Moellering R C, Jr., Swartz M N. The new cephalosporins. N Engl J Med 1976; 294: 24–28
   PubMed Web of Science ®Google Scholar
• Gustaferro C A, Steckelberg J M. Cephalosporin antimicrobial agents and related compounds. Mayo Clin Proc 1991; 66: 1064–1073
   PubMed Web of Science ®Google Scholar
• Cuchural G H, Jr., Tally F P, Jacobus N V. Comparative activities of newer p-lactam agents against members of the Bacteroides frag-ilis group. Antimicrob Agents Chemother. 1990; 34: 479–480
   PubMed Web of Science ®Google Scholar
• Lonks J R, Medeiros A A. The growing threat of antibiotic-resistant Streptococcus pneumoniae. Med Clin North Am 1995; 79: 523–535
   PubMed Web of Science ®Google Scholar
• Spratt B G. Distinct penicillin binding proteins involved in the division, elongation, and shape of E. coli K12. Proc Natl Acad Sci USA 1975; 72: 2999–3003
   PubMed Web of Science ®Google Scholar
• Okamoto M P, Nakahiro R K, Chin A, et al. Cefepime: A new fourth-generation cephalosporin. Am J Hosp Pharm 1994; 51: 463–477
   PubMedGoogle Scholar
• Rybak M. The pharmacokinetic profile of a new generation of parenteral cephalosporin. Ann Intern Med 1996; 100: 39S–44S
   Google Scholar
• Segreti J, Levin S. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin. Ann Intern Med 1996; 100: 45S–51S
   Google Scholar
• Cunha B A, Gill M V. Cefipime. Med Clin North Am 1995; 79: 721–732
   PubMed Web of Science ®Google Scholar
• Chow J W, Fine M J, Schlaes D M. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585–590
   PubMed Web of Science ®Google Scholar
• Karchmer A W. Cephalosporins. Principles and Practice of Infectious Diseases4th ed., G L Mandel, J E Bennett, R Dolin. Churchill Livingstone, New York 1995; 247–264
   Google Scholar
• Wright A J, Wilkowske C J. The penicillins. Mayo Clin Proc 1991; 66: 1047–1063
   PubMed Web of Science ®Google Scholar
• DeSarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some P-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995; 39: 232–237
   PubMed Web of Science ®Google Scholar
• Norrby S R, Newell P A, Faulkner K L, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995; 36: 207–223
   PubMed Web of Science ®Google Scholar
• Hughes W T, Amstrong D, Bodey G P, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551–573
   PubMed Web of Science ®Google Scholar
• Bodey G P. Empirical antibiotic therapy for fever in neutropenic patients. Clin Infect Dis 1993; 17: S378–S384
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Empiric Therapy for infections in the febrile, neutropenic, compromised host. Med Clin of North Am 1996; 79: 559–580
   Web of Science ®Google Scholar
• Pizzo P A. Management of fever in patients with cancer and treatment-induced neutropenia. N Eng J Med. 1993; 328: 1323–1332
   PubMed Web of Science ®Google Scholar
• Sanders J W, Powe N R, Moore R D. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis. J Infect Dis 1991; 164: 907–916
   PubMed Web of Science ®Google Scholar
• Winston D J, Ho W G, Young L S, Hewitt W L, Gale R P. Piperacillin plus amikacin therapy vs. carbenicillin plus amikacin therapy in febrile, granulocytopenic patients. Arch Intern Med 1982; 142: 1663–1667
   PubMed Web of Science ®Google Scholar
• Wade J C, Schimpff S C, Newman K A, et al. Piperacillin or ticar-cillin plus amikacin: A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med 1981; 71: 983–990
   PubMed Web of Science ®Google Scholar
• Lawson R D, Gentry L O, Bodey G P, et al. A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci 1984; 287: 16–23
   PubMed Web of Science ®Google Scholar
• Klastersky J, Glauser M P, Schimpff S C, , The European Organization for Research on Treatment of Cancer Antimicrobial Therapy Project Group, et al. Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bac-teremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 1986; 29: 263–270
   PubMed Web of Science ®Google Scholar
• The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of Holbrook and Lowy amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987; 317: 1692–1698
   PubMed Web of Science ®Google Scholar
• The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584–593
   PubMed Web of Science ®Google Scholar
• Pizzo P A, Hafhorn J W, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558
   PubMed Web of Science ®Google Scholar
• Bodey G P, Alvarez M E, Jones P G, et al. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother 1986 1986; 30: 211–214
   PubMed Web of Science ®Google Scholar
• Miller J A, Butler T, Beveridge R A, et al. Efficacy and tolerabili-ty of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. ClinTher 1993; 15: 486–499
   Google Scholar
• Leyland M J, Bayston K F, Cohen J, et al. A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother 1992; 30: 843–854
   PubMed Web of Science ®Google Scholar
• Freifeld A G, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–176
   PubMed Web of Science ®Google Scholar
• Rolston K V, Berkey P, Bodey G P, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152: 283–291
   PubMed Web of Science ®Google Scholar
• Jones P G, Rolston K VI, Fainstein V, et al. Aztreonam therapy in neutropenic patients with cancer. Am J Med 1986; 81: 243–248
   PubMed Web of Science ®Google Scholar